| SRRE (95% CI) | No. Studies | SRRE (95% CI) | No. Studies | SRRE (95% CI) | No. Studies | SRRE (95% CI) | No. Studies |
---|---|---|---|---|---|---|---|---|
Overall Exposure | Neighborhood | Domestic | Household | |||||
Gender | ||||||||
 Male | 4.80 (1.96, 11.76) | 7 | 5.71 (1.18, 27.54) | 4 | 3.24 (1.63, 6.45) | 5 | 2.40 (0.2, 26.70) | 1 |
 Female | 7.83 (3.30, 18.57) | 10 | 7.69 (1.91, 31.00) | 5 | 6.13 (2.42, 15.51) | 8 | 4.30 (1.20, 15.1) | 1 |
Fiber type | ||||||||
 Chrysotile | 3.56 (0.65,20.82) | 3 | 2.70 (0.03, 273.75) | 2 | 4.30 (1.24, 14.94) | 2 | – | 0 |
 Mixed | 7.63 (3.68, 15.82) | 8 | 10.36 (3.24, 33.16) | 7 | 7.40 (2.69, 20.37) | 5 | 1.30 (0.80,2.30) | 1 |
 Not reported | 2.66 (1.89, 3.74) | 11 | 3.53 (1.27, 9.81) | 6 | 2.70 (1.90, 3.85) | 7 | 2.23 (1.06, 4.70) | 4 |
Region | ||||||||
 Europe | 5.44 (3.16, 9.37) | 13 | 7.59 (3.24, 17.77) | 10 | 4.82 (2.46, 9.44) | 9 | 2.37 (1.34,4.19) | 4 |
 USA/Canada | 2.15 (1.01, 4.56) | 6 | 0.77 (0.30, 1.95) | 2 | 3.36 (1.68, 6.72) | 5 | – | 0 |
 South Africa/Egypt | 22.27 (6.35, 81.32) | 2 | 22.27 (6.35, 81.32) | 2 | – | 0 | – | 0 |
 Australia/South Pacific | 2.64 (0.92, 7.57) | 3 | 2.55 (1.09, 4.64) | 2 | 2.08 (0.80, 5.42) | 1 | 5.53 (0.15,205.3) | 2 |
Study Type | ||||||||
 Cohort | 12.62 (6.30, 25.26) | 5 | 11.59 (4.37, 30.79) | 4 | 8.17 (2.77, 24.13) | 3 | – | 0 |
 Case-Control | 2.12 (1.76, 2.56) | 19 | 3.37 (2.08, 5.46) | 12 | 2.88 (2.05, 4.03) | 12 | 2.41 (1.30, 4.48) | 6 |